(Q46862747)

25 December 2017

title

Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group (English)

1 reference

25 December 2017

1 reference

1 reference

1 reference

Cheryl A Brewer

1

1 reference

25 December 2017

John A Blessing

2

1 reference

25 December 2017

Robert A Nagourney

3

1 reference

25 December 2017

Mark Morgan

4

1 reference

25 December 2017

Parviz Hanjani

5

1 reference

25 December 2017

language of work or name

English

0 references

publication date

27 April 2006

1 reference

25 December 2017

published in

Gynecologic Oncology

1 reference

25 December 2017

volume

103

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

446-450

1 reference

25 December 2017

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Gemcitabine-induced pulmonary toxicity: case report and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Gemcitabine-associated hemolytic-uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Gemcitabine-induced radiation recall

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

Gemcitabine-cisplatin: a schedule finding study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.018

10.1016/J.YGYNO.2006.03.018

7 January 2021

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017